CRBU - Company ID 0001619856
The table below shows Caribou Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $2.40M | $2.20M | $2.67M | $2.35M | $2.02M | $3.46M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $20.61M | $22.40M | $27.69M | $35.53M | $30.42M | $35.48M |
Caribou Biosciences, Inc. reported annual revenue of $11.16M for fiscal year 2025. That is up 11.7% from $9.99M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $5.79M (FY 2019) to $11.16M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $8.07M |
| $9.20M |
| $10.40M |
| $9.73M |
| $9.84M |
| $11.48M |
| Operating income | -$26.28M | -$29.40M | -$47.58M | -$42.91M | -$38.24M | -$43.50M |
| Income tax | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 |
| Net income | -$25.09M | -$27.55M | -$54.10M | -$39.99M | -$34.68M | -$37.70M |
| EPS (diluted) | -$0.26 | -$0.30 | -$0.58 | -$0.43 | -$0.38 | -$0.42 |